

Safety and Efficacy of Ayurvedic Interventions and Yoga on Long Term Effects of COVID-19: a Structured Summary of a Study Protocol for a Randomized Controlled Trial

Babita Yadav (✉ drbabitayadav@gmail.com)

Central Council for Research in Ayurvedic Sciences

Amit Rai

Central Council for Research in Ayurvedic Sciences

Pallavi Suresh Mundada

Central Council for Research in Ayurvedic Sciences <https://orcid.org/0000-0003-3326-2165>

Richa Singhal

Central Council for Research in Ayurvedic Sciences

BCS Rao

Central Council for Research in Ayurvedic Sciences

Rakesh Rana

Central Council for Research in Ayurvedic Sciences

Narayanam Srikanth

Central Council for Research in Ayurvedic Sciences

Research Article

Keywords: Ashwagandha, Agastya Haritaki, Post-COVID, long-COVID, Respiratory function, SARS-CoV-2, Yoga, WHO, randomised controlled trial, protocol, COVID-19

Posted Date: May 13th, 2021

DOI: <https://doi.org/10.21203/rs.3.rs-490926/v1>

License:  This work is licensed under a Creative Commons Attribution 4.0 International License.

[Read Full License](#)

Abstract

Objectives:

Primary Objective

- To assess the efficacy of Ayurveda interventions and Yoga in rehabilitation of COVID-19 cases suffering with long term effects of COVID 19 as compared to WHO Rehabilitation Self-Management after COVID-19- Related Illness.

Secondary Objective

- To assess the safety of Ayurvedic interventions in cases suffering with long term effects of COVID 19

Trial design:

Multi-centric, randomized, controlled, parallel group, open-label, exploratory study. The study duration is 9 months and the intervention period is 90 days from the day of enrolment of the participant.

Main Text

Participants: Patients of either sex between 18 to 60 years, ambulatory, willing to participate, with history (not more than 4 weeks) of positive RT-PCR for COVID-19 or IgM antibodies positivity for SARS CoV-2, but having negative RT-PCR for COVID-19 at the time of screening will be considered eligible for enrolment in the study. Critically ill patients with ARDS (acute respiratory distress syndrome), requiring invasive respiratory support in the intensive care unit, known case of any malignancy, immune-compromised state (e.g. HIV), diabetes mellitus, active pulmonary tuberculosis, past history of any chronic respiratory disease, motor neuron disease, multiple sclerosis, stroke, impaired cognition, atrial fibrillation, acute coronary syndrome, myocardial infarction, severe arrhythmia, concurrent serious hepatic disease or renal disease, pregnant or lactating women, patients on immunosuppressive medications, history of hypersensitivity to the trial drugs or their ingredients, depressive illness (before COVID-19), diagnosed psychotic illnesses, substance dependence or alcoholism will be excluded.

The trial will be conducted at two medical colleges in Maharashtra, India.

Intervention and comparator:

Intervention Arm (Group-I): Ayurveda interventions including Agastya Haritaki six gram and Ashwagandha tablet 500 mg twice daily orally after meals with warm water and two sessions of yoga (morning 30 minutes and evening 15 minutes) daily for 90 days, as per the post-COVID-19 care protocol provided in National Clinical Management Protocol based on Ayurveda and Yoga for management of COVID-19 published by Ministry of AYUSH, Government of India.

Comparator Arm (Group-II): WHO Rehabilitation Self-Management after COVID-19 related illness for 90 days.

The trial drugs are being procured from a GMP certified pharmaceutical company.

Main outcomes:

Primary Outcome: Change in respiratory function to be assessed by San Diego shortness of breath Questionnaire, 6-minutes walk test and pulmonary function test.

Secondary Outcomes:

- Change in High-resolution Computed Tomography (HRCT) Chest
- Change in Fatigue score assessed by Modified Fatigue Impact Scale
- Change in Anxiety score assessed by Hospital Anxiety and Depression Scale Score
- Change in Sleep Quality assessed by Pittsburgh Sleep Quality Index
- Change in the quality of life assessed by COV19-QoL scale
- Safety of the interventions will be assessed by comparing hematological and biochemical investigations before and after the intervention period and Adverse Event/ Adverse drug reaction

Timelines for Outcome assessment: Subjective parameters and clinical assessment will be assessed at baseline, 15th day, 30th day, 60th day and 90th day. Laboratory parameters (CBC, LFT, KFT, HbA1c, Hs-CRP, D-dimer), Pulmonary function test and HRCT Chest will be done at baseline and after completion of study period i.e. 90th day.

Randomisation: Statistical package for Social Sciences (SPSS) version 15.0 is used to generate the random number sequences. The participants will be randomized to two study groups in the ratio of 1:1.

Blinding (masking): The study is open-label design. However, the outcome assessor will be kept blinded regarding the study group allocation of the participants.

Numbers to be randomised (sample size) Sample size: The sample size for the study is calculated assuming improvement in 6-minutes walk test by 40 meter in Group I and a change of 10 meter in Group II with a standard deviation of 50 meter based on the results of the previous studies, with 95% Confidence Level ($\alpha = 0.05$) and 80% power and expecting a dropout rate of 20%. The number of participants to be enrolled in the study should be approximately 55 in each group. Hence, a total of 110 participants will be enrolled in the trial at each study site.

Trial Status:

Participants' recruitment started on 1st May 2021. Anticipated end of recruitment is August 2021.

Protocol number: CCRAS-01 Protocol version number: 1.1, 13th January 2021.

Trial registration:

The trial is prospectively registered with the Clinical Trial Registry of India (CTRI) on 03rd March 2021 [CTRI/2021/03/031686].

Full protocol: The full protocol is attached as an additional file, accessible from the Journal website (Additional file 1). This communication serves as a summary of the key elements of the full protocol.

Declarations

Ethics approval and consent to participate:

The study protocol has been approved by the institutional Ethics committees of both the study centres viz., Government Medical College, Nagpur, India and Datta Meghe Institute of Medical Sciences, Wardha, India on 3rd February 2021 and 24th February 2021 (vide EC-CT-2019-0129 and EC/Pharmac/GMC/NGP/2309). The study will be conducted in accordance with the principles of the Declaration of Helsinki and the ICMR's National Ethical Guidelines for Biomedical and Health Research on Human Participants (2017). Written consent will be taken from all the eligible and willing participants before their screening. The study will be monitored by a Data and Safety Monitoring Board (DSMB).

Consent for publication:

The informed written consent from participants included their consent to publish unidentifiable data in journal research articles .

Availability of data and materials:

Raw data will be generated at study centres will be processed to the derived data supporting the findings of this study at CCRAS headquarters. It will be available from the corresponding author [BY] upon reasonable request.

Competing Interest:

None

Source of Funding:

Central Council for Research in Ayurvedic Sciences, Under Ministry of AYUSH, Government of India. The funding agency has designed this study and will analyze the data and publish the results as both medicines are classical Ayurveda formulations. It has no role in manufacturing and marketing the trial drugs.

Authors' Contributions:

BY conceived the study. PM and AR initiated the study design. Protocol was finalized with inputs from BCSR and NS. RS provided statistical inputs. All authors contributed to refinement of the study protocol and approved the final manuscript.

Acknowledgements:

Dr. R G Reddy, Assistant Director and Dr. Shekhar Namburi, Research Officer, Regional Ayurveda Research Institute, Nagpur for coordinating the collaboration for conducting this multi-center study. Dr. B. S. Sharma and Dr. Shruti Khanduri for coordinating the trial drug procurement.

References

References is not available with this version.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- [AdditionalFileCompleteProtocol.docx](#)